DataSet Record GDS4979: Expression Profiles Data Analysis Tools Sample Subsets
Title: Lapatinib effect on lapatinib-resistant ErbB2-positive cell line: dose response
Cluster AnalysisGDS4979 Cluster Image
Summary: Analysis of lapatinib-resistant ErbB2-positive cells treated with 0.1 or 1 uM lapatinib. Lapatinib is an EGFR/ErbB2 inhibitor used to treat ErbB2‐positive advanced or metastatic breast cancer. Results provide insight into the mechanisms underlying the development of resistance to lapatinib.
Organism: Homo sapiens
Platform: GPL6947: Illumina HumanHT-12 V3.0 expression beadchip
  • Komurov K, Tseng JT, Muller M, Seviour EG et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 2012;8:596. PMID: 22864381
Reference Series: GSE38376 Sample count: 18
Value type: count Series published: 2012/06/30